Synergy CHC Corp. Announces Financial Results for Q3 2025, Marking Its Eleventh Straight Quarter of Profitability
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 13 2025
0mins
Source: Newsfilter
Financial Performance: Synergy CHC Corp. reported a revenue increase to $8.0 million for Q3 2025, marking a 12.4% growth from the previous year, alongside a gross margin expansion to 70.9%. However, net income decreased to $125.3 thousand compared to $783.6 thousand in Q3 2024.
Strategic Partnerships: The company has expanded its retail presence through partnerships with major retailers like Kroger and Wakefern, enhancing distribution for its FOCUSfactor products across various channels in North America.
Capital and Growth Initiatives: Synergy completed a $4.4 million public offering in August 2025, providing additional working capital to support growth initiatives, including the launch of its beverage division.
Recognition and Leadership: FOCUSfactor was named the #1 Pharmacist Recommended OTC Memory Supplement for 2025-2026, reflecting the brand's strong market position and consumer trust, while the company appointed former Costco executive Teresa Thompson to its Board of Directors to bolster retail expertise.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNYR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNYR
Wall Street analysts forecast SNYR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNYR is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.820
Low
7.00
Averages
7.00
High
7.00
Current: 1.820
Low
7.00
Averages
7.00
High
7.00
About SNYR
Synergy CHC Corp. is a provider of consumer healthcare, beauty, and lifestyle products. The Company's brand portfolio includes FOCUSfactor and Flat Tummy. FOCUSfactor is a clinically studied brain health supplement and functional beverage line. Flat Tummy is a lifestyle brand that provides a suite of nutritional products to help women achieve their weight management goals. It has six additional, non-core brands are Hand MD is a complete hand-care brand to help maintain clean and healthy hands while reducing the signs of aging; Perfekt Beauty is in beauty line of products for the eyes, lips, brows, cheeks and skin; Sneaky Vaunt is in lingerie brand with a line of women’s shapewear, bralettes and panties; The Queen Pegasus is in eyelash enhancement products for longer, thicker, natural lashes; Neuragen is in fast-acting topical treatments for neuropathic (nerve) pain, and UrgentRx is in line of fast-acting, portable, powdered over-the-counter medications.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
New to The Street Broadcasts Show #716 Featuring SDST and Others
- Broadcast Timing: New to The Street will air Show #716 tonight at 6:30 PM Eastern Time on Bloomberg Television, enhancing its influence in the business media landscape by showcasing various public companies.
- Company Highlights: The episode will spotlight Stardust Power Inc. (NASDAQ:SDST), BioVie Inc. (NASDAQ:BIVI), and Roadzen Inc. (NASDAQ:RDZN), showcasing innovations in critical minerals, biotechnology, and AI-driven mobility and insurance solutions, aimed at attracting investor interest.
- Celebrity Features: The show will also include special segments with Kelsey Grammer discussing his new book KAREN and Andrew Shaw introducing his nonprofit 250DAYS.ORG, emphasizing the importance of mental health awareness and recovery, thereby enhancing the program's social impact.
- International Expansion Plans: New to The Street plans to launch its international version in the MENA region on January 24, 2026, further expanding its global reach, while also preparing to launch the Spanish-language platform Nuevo En La Calle, showcasing its diversified media strategy.
Continue Reading
New to The Street Highlights Blockchain and Oncology Innovations in Episode #710
- Blockchain Infrastructure Acceleration: TokenFI's Chief Revenue Officer Pedro Vidal discussed strategies for accelerating institutional adoption of blockchain tokenization, aiming to build scalable, compliance-ready infrastructure for real asset issuance, which is expected to drive transformation in financial markets.
- New Oncology Treatment Platform: NeOnc Technologies' CEO Amir Heshmatpour introduced an intranasal drug delivery platform targeting aggressive brain cancers along with its clinical and regulatory roadmap, potentially providing new treatment options and improving survival rates for patients.
- AI-Driven Drug Discovery: Lantern Pharma's CEO Panna Sharma outlined their AI-driven approach to oncology drug discovery, enhancing research speed and capital efficiency, which is anticipated to increase clinical success rates and expedite new drug market entry.
- Infrastructure Investment Strategy: Mataterra Holdings' co-chairmen Monika Proffitt and Douglas Anderson provided strategic insights on global infrastructure development and real asset tokenization, emphasizing the importance of capital formation to meet future market demands.
Continue Reading